Created at	Source	Raw Value	Validated value
June 23, 2021, 1:30 a.m.	usa	Number of Patients who Progressed to Severe Disease (Clinical stage 4 or 5);Time Required for Patients on Treatment Arm to Progressed to Severe Disease (Clinical stage 4 or 5)	Number of Patients who Progressed to Severe Disease (Clinical stage 4 or 5);Time Required for Patients on Treatment Arm to Progressed to Severe Disease (Clinical stage 4 or 5)
June 15, 2021, 12:32 a.m.	usa	Age Distribution of the Patients;Changes in Serum Absolute Lymphocyte Counts;Changes in Serum Absolute Neutrophil Counts;Changes in Serum Alanine Aminotransferase (ALT);Changes in Serum Creatinine;Changes in Serum C-Reative Protein (CRP);COVID-19 Clinical Staging at Time of Enrolment;COVID-19 Clinical Staging at Time of Hospitalization;Gender Distribution of Patients;Percentage of Patients With Underlying Illness;Radiograph Diagnosis of Patient Prior to Enrolment;Treatment-Related Adverse Events as Assessed by CTCAE v4.0	Age Distribution of the Patients;Changes in Serum Absolute Lymphocyte Counts;Changes in Serum Absolute Neutrophil Counts;Changes in Serum Alanine Aminotransferase (ALT);Changes in Serum Creatinine;Changes in Serum C-Reative Protein (CRP);COVID-19 Clinical Staging at Time of Enrolment;COVID-19 Clinical Staging at Time of Hospitalization;Gender Distribution of Patients;Percentage of Patients With Underlying Illness;Radiograph Diagnosis of Patient Prior to Enrolment;Treatment-Related Adverse Events as Assessed by CTCAE v4.0
June 12, 2021, 12:32 a.m.	usa	Age Distribution of the Patients;Changes in Serum Absolute Lymphocyte Counts;Changes in Serum Absolute Neutrophil Counts;Changes in Serum Alanine Aminotransferase (ALT);Changes in Serum Creatinine;Changes in Serum C-Reative Protein (CRP);COVID-19 Clinical Staging at Time of Enrolment;COVID-19 Clinical Staging at Time of Hospitalization;Gender Distribution of Patients;Laboratory Results within 48 Hours of Enrolment;Percentage of Patients With Underlying Illness;Radiograph Diagnosis of Patient Prior to Enrolment;Treatment-Related Adverse Events as Assessed by CTCAE v4.0	Age Distribution of the Patients;Changes in Serum Absolute Lymphocyte Counts;Changes in Serum Absolute Neutrophil Counts;Changes in Serum Alanine Aminotransferase (ALT);Changes in Serum Creatinine;Changes in Serum C-Reative Protein (CRP);COVID-19 Clinical Staging at Time of Enrolment;COVID-19 Clinical Staging at Time of Hospitalization;Gender Distribution of Patients;Laboratory Results within 48 Hours of Enrolment;Percentage of Patients With Underlying Illness;Radiograph Diagnosis of Patient Prior to Enrolment;Treatment-Related Adverse Events as Assessed by CTCAE v4.0